Glypressin (Terlipressin Acetate)

Glypressin is employed in clinical settings where controlled vasoconstriction is required. It is commonly used:

• To manage acute hypotension associated with septic shock when other vasopressors are insufficient.
• As an adjunct in the treatment of bleeding esophageal varices.
• To support hemodynamic stability during certain surgical procedures.
• In the management of hepatorenal syndrome under specialist supervision.
• For experimental or off‑label use in refractory shock, following physician judgment.

Side effects of Glypressin vary in frequency and severity. Common adverse reactions are typically mild and reversible, while serious events are less frequent but may require medical attention.

Common

• Headache
• Nausea
• Abdominal discomfort
• Flushing or warmth at the infusion site
• Transient hypertension

Serious

• Severe hypertension or hypertensive crisis
• Cardiac arrhythmias
• Ischemic complications (e.g., myocardial ischemia)
• Peripheral ischemia or necrosis
• Acute renal impairment

Before initiating Glypressin therapy, several safety considerations should be reviewed. Physicians should assess the following:

• Baseline cardiovascular status, including history of ischemic heart disease.
• Renal function, especially in patients with pre‑existing kidney disease.
• Presence of peripheral vascular disease or risk of ischemia.
• Potential for hypersensitivity to terlipressin or formulation components.
• Concomitant use of other vasoconstrictors or inotropes.
• Pregnancy and lactation status, as safety data are limited.

Glypressin may interact with other medications, influencing its efficacy or safety profile. Interaction management is essential.

Avoid

• Concurrent use with other potent vasopressors (e.g., norepinephrine, phenylephrine) without close monitoring.
• Combination with drugs that markedly increase systemic vascular resistance (e.g., ergot alkaloids).

Use with caution

• Beta‑blockers, which may blunt compensatory tachycardia.
• Diuretics, which can affect intravascular volume.
• Anticoagulants, due to potential for ischemic complications.
• Drugs metabolized by hepatic pathways that may be altered by changes in hepatic blood flow.